Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Immunotherapy.

Medical University of South Carolina, Charleston, SC, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Charleston, SC
Treatments:ImmunotherapyHospital:Medical University of South Carolina
Drugs:Journal:Link
Date:Mar 2015

Description:

Patients:
This phase 2 study involved 21 previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma patients. The median patient age was 63 years and 81% were male.

Treatment:
Patients received immunotherapy with ofatumumab (human anti-CD20 monoclonal antibody that directs immune system to attack cancer cells) and lenalidomide.

Toxicities:
There was one treatment-related death due to infection. Grade 4 neutropenia and thrombocytopenia, grade 3 tumor flare reaction, and grade 2 infusion related reaction and fatigue were also reported.

Results:
The median overall survival was 21.5 months.

Support:
This study was supported by GlaxoSmithKline.

Correspondence: Dr. Luciano J. Costa; email: [email protected]



Back